Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.
Fixed-ratio combination
GLP-1RA
Insulin
Real-world study
Type 2 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
02
09
2022
accepted:
17
10
2022
pubmed:
5
11
2022
medline:
5
11
2022
entrez:
4
11
2022
Statut:
ppublish
Résumé
Combining basal insulin (BI) with glucagon-like peptide-1 receptor agonist (GLP-1RA) is recognized as a relevant option to optimize glucose control in type 2 diabetes (T2D). The EASY real-world study aimed to evaluate the modalities of initiation and the effectiveness of the insulin Degludec plus Liraglutide (IDegLira) fixed-ratio combination in the French health care system. A retrospective analysis included all patients with T2D and prior injectable therapy (GLP1-RA and/or insulin) who started treatment with IDegLira from September 2016 to December 2017 in 11 French diabetes centers. Baseline characteristics, reasons for IDegLira initiation, and modes of implementation were collected from the medical records. Changes in HbA IDegLira was initiated in 629 patients previously treated with GLP-1RA alone (11.6%), insulin alone (31.5% including 16.5% with BI and 14.9% with multiple daily injections [MDI]) or a free combination of GLP-1RA and insulin (56.9% including 44.8% with BI and 12.1% with MDI), associated or not with oral agents. IDegLira starting dose (mean of 29 ± 11 dose steps) most often exceeded the recommended dose, and was significantly correlated with prior BI but not GLP-1RA dosage. At initiation, mean age, body mass index (BMI) and HbA While providing new information on the use of IDegLira in the French healthcare system, these data confirm the effectiveness of this fixed-ratio combination in the management of T2D.
Identifiants
pubmed: 36331712
doi: 10.1007/s13300-022-01327-8
pii: 10.1007/s13300-022-01327-8
pmc: PMC9663793
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1947-1963Informations de copyright
© 2022. The Author(s).
Références
Diabetes Obes Metab. 2018 Apr;20(4):954-962
pubmed: 29205856
Diabetes Ther. 2019 Oct;10(5):1869-1878
pubmed: 31347100
JAMA. 2016 Mar 1;315(9):898-907
pubmed: 26934259
Lancet. 2014 Dec 20;384(9961):2228-34
pubmed: 25220191
Diabetes Care. 2018 May;41(5):1009-1016
pubmed: 29483185
Diabetes Ther. 2017 Aug;8(4):739-752
pubmed: 28721686
Diabetes Ther. 2022 Aug;13(8):1483-1497
pubmed: 35717487
Diabetes Care. 2021 Jun;44(6):1353-1360
pubmed: 33883195
Diabetes Obes Metab. 2013 Jan;15(1):3-14
pubmed: 22646532
Diabetes Ther. 2017 Feb;8(1):101-114
pubmed: 27943107
Diabetes Ther. 2021 Aug;12(8):2133-2147
pubmed: 34268675
Diabetes Ther. 2020 Jan;11(1):185-196
pubmed: 31808132
Drugs. 2020 Feb;80(2):147-165
pubmed: 31960258
Diabetes Ther. 2021 Jan;12(1):197-209
pubmed: 33104959
Diabetes Care. 2014 Nov;37(11):2926-33
pubmed: 25114296
Diabetes Ther. 2020 Jul;11(7):1579-1589
pubmed: 32506223
Diabetes Obes Metab. 2021 Jan;23(1):136-146
pubmed: 32991041
Diabetes Care. 2017 Apr;40(4):614-624
pubmed: 28325801
Diabetes Care. 2022 Nov 1;45(11):2753-2786
pubmed: 36148880
Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):923-931
pubmed: 33577047
Diabetes Ther. 2020 Aug;11(8):1807-1820
pubmed: 32617849
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143
pubmed: 34964831
Adv Ther. 2019 Feb;36(2):265-277
pubmed: 30610613
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Diabetes Res Clin Pract. 2021 Aug;178:108958
pubmed: 34280468